Scancell's iSCIB1+ Immunotherapy Shows 74% Progression-Free Survival in Phase II Melanoma Trial
核心洞察
Scancell's SCOPE phase II melanoma (搜索) trial achieved 74% progression-free survival at 16 months with iSCIB1+ (搜索) immunotherapy, compared to 46% at 12 months for standard checkpoint inhibitor therapy.
The ImmunoBody candidate demonstrated clinically meaningful benefits across all patient subgroups, including those with BRAF (搜索) mutations, varying PD-L1 (搜索) status, and prior checkpoint inhibitor treatment.
The successful trial results have confirmed parameters for a registrational phase III study planned to begin in late 2026, while strengthening the company's position for potential partnerships.
Scancell Holdings PLC (搜索) has reported promising results from its phase II SCOPE trial evaluating iSCIB1+ (搜索), an ImmunoBody immunotherapy candidate for melanoma (搜索) treatment. The trial achieved a 74% progression-free survival rate at 16 months, significantly outperforming the standard of care benchmark of 46% at 12 months.
Strong Efficacy Signal Across Patient Populations
The SCOPE study demonstrated what CEO Phillip L'Huillier characterized as a "really strong and durable benefit" when iSCIB1+ (搜索) is added to existing melanoma (搜索) treatments. The therapy showed clinically meaningful benefits across challenging patient subgroups where current therapies typically show reduced effectiveness, including patients with BRAF (搜索) mutations, varying PD-L1 (搜索) status, and those who had received prior checkpoint inhibitor treatment.
The standard of care comparison includes dual checkpoint inhibitors Ipilimumab and Nivolumab, representing the current therapeutic backbone for advanced melanoma (搜索) patients.
Trial Objectives Met, Phase III Parameters Confirmed
According to L'Huillier, the SCOPE study "has met the objectives that we set out for it," providing crucial clarity on dosing regimens, patient population selection, and overall trial design for the upcoming registrational phase III study. The company has received supportive regulatory feedback regarding their development strategy.
The successful completion of the phase II trial establishes the foundation for Scancell's next major clinical milestone, with the phase III study scheduled to begin in late 2026.
Strategic Positioning Enhanced
The positive clinical data has materially strengthened Scancell's position for both partnership discussions and financing opportunities. L'Huillier indicated the company is pursuing a dual-track strategy, evaluating options to either secure a development partner or proceed independently with the phase III program.
The ImmunoBody platform represents Scancell's lead therapeutic approach, designed to enhance immune system recognition and response against cancer cells. The technology aims to address limitations in current immunotherapy approaches by targeting specific tumor-associated antigens.